Emerging Challenges in Primary Care: 2018

Managing Lipids and Cardiovascular Risk: Using the Data to Optimize Care



Final Live Activities Outcomes Report Amgen Grant ID: IME-145797

January 14, 2019






Executive Summary

- This curriculum discussed the management of hyperlipidemia, with a focus on PCSK9 inhibitors.
- Substantial improvements were measured in learners' awareness of the barriers to initiating PCSK9 inhibitor therapies and in strategies to overcome them, as well as clinical trials investigating treatment with PCSK9 inhibitors.



Pre to Post-Test Results By Learning Objective



- LO1: 101% Improvement: Describe the findings from recent trials of PCSK9i hypercholesterolemia treatments on cardiovascular outcomes.
- **LO2: 44% Improvement**: Discuss current guidelines and recommendations for the management of hyperlipidemia in high risk patients.
- **LO3: 44% Improvement**: Incorporate current data into secondary prevention treatment strategies for patients with the highest cardiovascular risk.
- **LO4: 64% Improvement**: Recognize barriers to access for PCSK9 monoclonal antibody therapy and discuss strategies to overcome them.

Impact

- 3,019 attendees were reached via both online and live formats, with significant gains observed across cohorts and modalities from Pre-test to Post-test.
- Learners demonstrated substantial increases in their measured knowledge of trials of two new PCSK9 inhibitors and strategies for securing their approval in practice.
- Despite substantial improvements across the intervention, learners remain challenged in their knowledge of recent trials on PCSK9 inhibitors and treatment selection for patients with high cardiovascular risk.

Curriculum Patient Impact

In the evaluation, learners (N = 3,019) were asked to report how many patients with hyperlipidemia they see in any clinical setting per week by selecting a range. The resulting distribution of learner responses was then extrapolated to reflect the total number of learners who have attended the onsite and online meetings.

15095–54,946 patients on a weekly basis

The findings reveal that this education has the potential to impact

2,857,192

patients on an annual basis.

15095– 54,946





Course Director

Karol E. Watson, MD, PhD

Professor of Medicine/Cardiology Co-director, UCLA Program in Preventive Cardiology Director, UCLA Barbra Streisand Women's Heart Health Program Los Angeles, CA

Activity Planning Committee

Gregg Sherman, MD Michelle Frisch, MPH, CHCP Sandy Bihlmeyer, M.Ed. Sheila Lucas, CWEP Cassandra A. McCullough, MBA Harvey C. Parker, Ph.D., CHCP

RealCME

Faculty

Ola Akinboboye, MD, MPH, MBA

Associate Professor of Clinical Medicine Cornell University Past President, Association of Black Cardiologists Medical Director, Queens Heart Institute Rosedale, NY

Keith C. Ferdinand, MD, FACC, FAHA, FNLA, FASH

Professor of Medicine, Tulane University School of Medicine Tulane Heart and Vascular Institute New Orleans, LA

Robert L. Gillespie, MD, FACC, FASE, FASNC

Immediate Past Chairman of the Board, Association of Black Cardiologists Director of Nuclear Imaging Sharp Rees-Stealy Medical Group San Diego, CA **David Montgomery, MD, PhD, FACC** Preventive Cardiologist Piedmont Heart Institute Atlanta, GA

Karol E. Watson, MD, PhD

Professor of Medicine/Cardiology Co-director, UCLA Program in Preventive Cardiology Director, UCLA Barbra Streisand Women's Heart Health Program Los Angeles, CA






Commercial Support

The Emerging Challenges in Primary Care: 2018 series of CME activities were supported through educational grants or donations from the following companies:

- Actelion Pharmaceuticals US, Inc.
- Amgen, Inc.
- AstraZeneca Pharmaceuticals LP
- Boehringer Ingelheim Pharmaceuticals, Inc.
- ER/LA Opioid Analgesic REMS Program Companies
- ✤Lilly USA, LLC
- Novo Nordisk, Inc.
- Sanofi Genzyme and Regeneron Pharmaceuticals
- Sanofi US









Learning Objectives

- Describe the findings from recent trials of PCSK9i hypercholesterolemia treatments on cardiovascular outcomes.
- Discuss current guidelines and recommendations for the management of hyperlipidemia in high risk patients.
- Incorporate current data into secondary prevention treatment strategies for patients with the highest cardiovascular risk.
- Recognize barriers to access for PCSK9 monoclonal antibody therapy and discuss strategies to overcome them.







Emerging Challenges in Primary Care 2018 17th Annual Regional and Online CME Conference Series

Curriculum Overview

9 Accredited Live Regional Symposia August 11, 2018 – October 28, 2018



Enduring CME Symposium Webcast

Launch Date: October 15, 2018

End Date: October 14, 2019

Available at: http://bit.ly/2018ECLipidsWebcast



Speaker David Montgomery, MD Preventive Cardiologist Piedmont Heart Institute Atlanta, GA

RealCME




1 Accredited Live Virtual Symposium:

September 22, 2018



Clinical Highlights eMonograph

eMonograph, containing key teaching points from the CME activity, was distributed 1 week after the meeting to all attendees.





Outcomes Methodology

Learning outcomes were measured using matched Pre-Test and Post-Test scores for Knowledge, Performance, Confidence, and practice strategy and across all of the curriculum's Learning Objectives.

Outcomes Metric	Definition	Application Differences between Pre-Test, Post- Test, and PCA score averages		
Percentage change	This is how the score changes resulting from the education are measured. The change is analyzed as a relative percentage difference by taking into account the magnitude of the Pre-Test average.			
P value (p)	This is the measure of the statistical significance of a difference in scores. It is calculated using dependent or independent samples t-tests to assess the difference between scores, taking into account sample size and score dispersion. Differences are considered significant for when $p \le .05$.	Significance of differences between Pre-Test, Post-Test, and PCA scores and among cohorts		
Effect size (d)	This is a measure of the strength/magnitude of the change in scores (irrespective of sample size). It is calculated using Cohen's d formula, with the most common ranges of d from 0-1: d < .2 is a small effect, d=.28 is a medium effect, and d > .8 is a large effect.	Differences between Pre-Test and Post-Test score averages		
Power	This is the probability (from 0 to 1) that the "null hypothesis" (no change) will be appropriately rejected. It is the probability of detecting a difference (not seeing a false negative) when there is an effect that is dependent on the significance (p), effect size (d), and sample size (N).	Differences between Pre-Test and Post-Test score averages		
Percentage non-overlap	This is the percentage of data points at the end of an intervention that surpass the highest scores prior to the intervention. In this report, it will reflect the percentage of learners at Post-Test who exceed the highest Pre-Test scores.	Differences between Pre-Test and Post-Test score averages		






Participation


2018 Meeting/Simulcast	Date	Attendees
Anaheim, CA	8/11/18	204
Houston, TX	8/18/18	245
Troy, MI	8/25/18	220
Troy, MI Simulcast	8/25/18	306
Ft. Lauderdale, FL	9/8/18	308
Nashville, TN	9/15/18	162
Virtual Symposium	9/22/18	601
Uniondale, NY	10/6/18	286
Uniondale, NY Simulcast	10/6/18	355
San Mateo, CA	10/13/18	94
Denver, CO	10/20/18	128
San Diego, CA	10/27/18	110
Total		3,019











Level 1: Demographics and Patient Reach

None 78.41% Specialties: Endocrinology 1.73% 1 - 5Gastroenterology 0.61% Psychiatry/Neurology 0.41% 6-10 Rheumatology 0.10% 11-15 16-20 6.31% 4.28% 4.07% 4.07% 2.85% 21-25 Hospitalist **Primary Care** Other Emergency Cardiology Specialty > 25 Medicine / Above Critical Care 0% 10% 20% 30% Average number of patients with hyperlipidemia Patient Care Focus: 91% seen each week per clinician: 13 **Profession** Years in Practice 53.11% 38.27% 26.36% 29.00% 18.56% 16.81% 8.95% 4.05% 3.11% 1.79% < 5 5 - 1011 - 20> 20 NP MD PA RN DO Other RealCME

Specialty

Patients with hyperlipidemia seen each week, in any clinical setting:

Association of Black Cardiologists, Inc








Learning Objectives Analysis


(N = 1057 - 1454)



- Substantial and significant gains (ranging from 44% to 101%) from low Pre-Test averages were achieved on all Learning Objectives.
- The Post-Test average remained comparatively low (76%) on the Learning Objective related to PCSK9i trials, despite a substantial gain (101%) from Pre-Test. Other Learning Objectives showed higher Post-Test scores (81% and 88%).
 - The substantial score increase on the Learning Objective on PCSK9i trials was driven by the score increases on two Knowledge questions about the FOURIER and ODYSSEY trials.



Learning Domain Analysis



Post-Test Pre-Test

*significant at the $p \le 0.05$ level, matched data

Significant gains (32%–85%) were achieved in all learning domains.

- The substantial 85% increase in Knowledge was due to increases of 96% and 102% on two Knowledge * guestions related to the FOURIER and ODYSSEY trials on the PCSK9 inhibitors evolocumab and alirocumab.
- The 44% increase in Performance was due to increases (ranging from 15% to 57%) on the use of * atorvastatin, ezetimibe and PCSK9 inhibitors for a patient with hyperlipidemia who is currently taking a statin.
- Learners substantially (70%) increased their reported Confidence in their ability to determine which patients ٠. may benefit from the use of a PCSK9 inhibitor, from a low Pre-Test average rating of 2.0 to a moderate Post-Test rating of 3.5.
- There was also a substantial (32%) increase (from an average rating of 3.0 to 3.9) in learners' reported * intent to consider non-statin therapies for patients with high ASCVD risk and LDL-C not at recommended target, despite the use of maximally tolerated statin. RealCME



Curriculum/Activity Intervention Effect

Learning Domain	Effect Size*	% Non-Overlap
Knowledge	1.058	62.59%
Performance	0.766	50.34%

Effect Size Definition: This is a standardized measure of the strength/magnitude of the change in scores, irrespective of sample size. This metric quantifies the association between outcome and exposure to education, in a way which makes meta-analysis possible. There exist many types of effect size measures, each appropriate in different situations. We select Cohen's *d* for this analysis, which is a standardized difference in mean. Most commonly, *d* ranges from 0–1: d < 0.2 is a small effect, d = 0.2-0.8 is a medium effect, and d > 0.8 is a large effect.





Learning Domain by Professional Cohort

Learning Domain		Nurse Practitioner				Physician			
	N	Pre-Test	Post-Test	% Change	N	Pre-Test	Post-Test	% Change	
Knowledge	328	37.32% (35.70%)	77.71% (35.09%)	+108.22%*	210	40.52% (34.72%)	78.12% (31.83%)	+92.79%*	
Performance	358	54.07% (34.64%)	82.82% (26.71%)	+53.16%*	214	57.90% (33.28%)	79.73% (27.55%)	+37.70%*	
Confidence	272	1.90 (1.01)	3.41 (0.95)	+79.15%*	179	2.12 (1.11)	3.53 (0.97)	+66.75%*	
Practice	297	2.90 (1.11)	3.96 (0.87)	+36.47%*	190	3.02 (1.11)	3.90 (0.90)	+29.32%*	

*significant at the p ≤ 0.05 level


- Nurse practitioners (NPs) and physicians demonstrated statistically significant gains in all learning domains.
- In all learning domains, NPs demonstrated modestly lower Pre-Test scores compared to physicians; however, the greater gains achieved by NPs minimized or eliminated any Post-Test score differences.
 - In Performance and practice strategy, the greater gains of NPs resulted in Post-Test (final) scores modestly exceeding those of physicians.





4-Week Retention Analysis

(N = 694)



At follow-up:


- Statistically significant net gains were measured from Pre-Test to the Post Curriculum Assessment (PCA) in all learning domains.
- In all learning domains, score slippage from Post-Test to the PCA occurred, particularly in the Knowledge and Performance domains, reinforcing the need for continued education on the management of hyperlipidemia.





(4-week Post Assessment)


Please select the specific areas of *skills, or practice behaviors*, you have improved regarding the treatment of patients with hypercholesterolemia since this CME activity. (Select all that apply.) N=694





(4-week Post Assessment)

What specific *barriers* have you encountered that may have prevented you from successfully implementing strategies for patients with hypercholesterolemia since this CME activity? (Select all that apply.) N=694







Identified Learning Gap 1 of 2: Recent clinical trials on PCSK9 inhibitors

Despite an improvement of 102%, learners remained challenged on a Knowledge question which addressed a recent clinical trial on a PCSK9 inhibitor (alirocumab) and its impact on risk for major cardiovascular events.

In the ODYSSEY trial, what was the relative risk reduction in the primary outcome (major cardiovascular events) with alirocumab compared to placebo?

Results:

• At Post-Test, 68% of learners correctly answered: "15%."





Identified Learning Gap 2 of 2:

Treatment selection for patients at high cardiovascular risk

Learners also demonstrated low final scores on two RealIndex (Performance) items related to treatment selection for a patient with a history of hypertension and dyslipidemia, specifically whether atorvastatin and a PCSK9 inhibitor should be initiated.

70-year-old woman, 15-year history of hypertension, 10-year history of dyslipidemia. NSTEMI 1 year ago, LDL-C is 88 mg/dL. Current medications include lisinopril/hydrochlorothiazide 40/25 mg qd, metoprolol tartrate 100 mg bid, rosuvastatin 40 mg qd, and aspirin 81 mg qd.

After reviewing the brief scenario above, please rate these statements as consistent with or not consistent with best clinical practice:

Results:

• In learners' final RealIndex, 65% of learners correctly classified as **not consistent:** "switch to atorvastatin 80 mg".






Overall Educational Impact

- ✤ Significant improvements (ranging from 32% 85%) were seen across all learning domains.
 - The cohort analysis of professions showed that NPs demonstrated greater score increases from modestly lower Pre-Test (baseline) scores compared to physicians; these increases minimized their Post-Test (final) score differences.
 - Live onsite learners demonstrated substantially higher Post-Test (final) averages than online participants in the Knowledge domain (83% for live onsite vs. 67% for live online), with comparable scores in Performance, Confidence and Practice strategy.
 - Analysis of learning retention in the PCA showed that significant net gains from Pre-Test (baseline) were measured in all learning domains (8% – 52%). The greatest net increase was measured in learners' reported Confidence in their ability to determine which patients may benefit from the use of a PCSK9 inhibitor (2.0 at Pre-Test to 3.1 in PCA).
- Significant improvements (ranging from 44% 101%) were measured across all Learning Objectives. An especially high Post-Test score (88%) was measured on the Learning Objective on recognizing barriers to access for PCSK9 monoclonal antibody therapy and discussing strategies to overcome them. Moderately high Post-Test scores (76% 81%) were measured on the other three Learning Objectives.
 - Across three of the four Learning Objectives, onsite learners achieved similar Post-Test scores compared to live online learners, from similar Pre-Test scores. The exception was Learning Objective 1 (describing the finding of recent trials of PCSK9i treatments), in which live onsite learners demonstrated substantially greater score increases from similar Pre-Test scores..
- The analysis of the Knowledge and Performance domains identified two persistent learning gaps related to recent trials on PCSK9 inhibitors and treatment selection for patients with high cardiovascular risk.
 - Despite an improvement of 102%, learners remained challenged on the results of the ODYSSEY trials, only 68% of learners correctly answered at Post-Test that there was a 15% risk reduction of cardiovascular events when comparing the PCSK9 inhibitor alirocumab to a placebo.
 - On the RealIndex Performance metric, which presented a 70-year-old woman with a 15-year history of hypertension and a 10-year history of dyslipidemia, only 65% of learners correctly classified "Switch to atorvastatin 80 mg" as **not consistent.**











Learning Objectives Analysis – Live Onsite vs. Live Online Audience

- "Live onsite learners" include only those attending in-person meetings.
- "Live online learners" include those from both the Simulcast and Virtual Symposium.

	Live Onsite Learners				Live Online Learners			
Learning Objective	N	Pre-Test	Post-Test	% Change	N	Pre-Test	Post-Test	% Change
Describe the findings from recent trials of PCSK9i hypercholesterolemia treatments on cardiovascular outcomes.	985	38.32% (38.51%)	80.10% (34.17%)	+109.01%*	325	35.34% (41.31%)	62.35% (44.29%)	+76.42%*
Discuss current guidelines and recommendations for the management of hyperlipidemia in high risk patients.	1064	56.53% (34.60%)	81.08% (27.85%)	+43.42%*	390	54.95% (35.70%)	79.21% (30.78%)	+44.15%*
Incorporate current data into secondary prevention treatment strategies for patients with the highest cardiovascular risk.	1064	56.53% (34.60%)	81.08% (27.85%)	+43.42%*	390	54.95% (35.70%)	79.21% (30.78%)	+44.15%*
Recognize barriers to access for PCSK9 monoclonal antibody therapy and discuss strategies to overcome them.	858	51.86% (49.97%)	87.88% (32.64%)	+69.44%*	199	60.30% (48.93%)	87.94% (32.57%)	+45.83%*

*significant at the $p \le 0.05$ level

- On three of the four Learning Objectives, live onsite learners and live online learners had similar Post-Test scores.
- On the Learning Objective related to the findings of recent trials of PCSK9i treatments, live onsite * learners demonstrated substantially greater score increases and Post-Test scores, from similar Pre-Test scores, compared to live online learners.
- On the Learning Objective related to barriers to access for PCSK9 monoclonal antibody therapy, live online learners demonstrated a higher score at Pre-Test. However, the greater gain of live onsite learners eliminated any Post-Test score difference.



Learning Domain Analysis – Live Onsite vs. Live Online Audience

- "Live onsite learners" include only those attending in-person meetings.
- "Live online learners" include those from both the Simulcast and Virtual Symposium.

Learning Domain	Live Onsite Learners				Live Online Learners			
	N	Pre-Test	Post-Test	% Change	N	Pre-Test	Post-Test	% Change
Knowledge	1064	43.20% (34.45%)	82.71% (27.91%)	+91.44%*	353	41.00% (39.57%)	66.90% (41.01%)	+63.18%*
Performance	1064	56.53% (34.60%)	81.08% (27.85%)	+43.42%*	390	54.95% (35.70%)	79.21% (30.78%)	+44.15%*
Confidence	831	2.08 (1.09)	3.56 (0.97)	+71.21%*	276	1.93 (0.92)	3.20 (0.90)	+65.85%*
Practice	848	2.96 (1.12)	3.92 (0.94)	+32.52%*	301	2.98 (1.06)	3.94 (0.92)	+32.22%*

*significant at the $p \le 0.05$ level


- Live onsite and live online learners achieved substantial and significant score improvements across all learning domains.
- Live onsite learners demonstrated moderately higher Pre-Test (baseline) scores in Knowledge, Performance, and Confidence compared to live online learners. The greater gains of live onsite learners in these domains resulted in substantially higher Post-Test (final) scores.
- In practice strategy, scores and gains were comparable.






Knowledge Questions:

In the FOURIER trial, what was the number-needed-to-treat to prevent an instance of the primary outcome (major cardiovascular events) with evolocumab compared to placebo?



In the ODYSSEY trial, what was the relative risk reduction in the primary outcome (major cardiovascular events) with alirocumab compared to placebo?






Knowledge Questions (continued):

N = (1139 - 1336)

Which of the following strategies has demonstrated high rates of approval for the use of PCSK9 inhibitors?










Performance Questions

70-year-old woman, 15-year history of hypertension, 10-year history of dyslipidemia. NSTEMI 1 year ago, LDL-C is 88 mg/dL. Current medications include lisinopril/hydrochlorothiazide 40/25 mg qd, metoprolol tartrate 100 mg bid, rosuvastatin 40 mg qd, and aspirin 81 mg qd.

After reviewing the brief scenario above, please rate these statements as consistent with or not consistent with best clinical practice:




Confidence & Practice Questions

N = (1363–1502)

Confidence Question:

How confident are you in your ability to determine which patients may benefit from use of a PCSK9 inhibitor?



Practice Question:

How often do you consider non-statin therapies for patients with high ASCVD risk and LDL-C not at recommended target, despite use of maximally tolerated statin?

